Dutch regulators investigate Biogen over MS drug market conduct

Dutch antitrust regulators are looking into claims that Biogen may have used its strong market position unfairly in the area of MS treatments and related blood tests, according to STAT. The investigation focuses on whether Biogen's conduct restricted competition.

This move signals increased regulatory scrutiny for large pharma companies, especially those with a significant share in specialised treatment markets. Senior executives should assess their own practices for compliance and anticipate possible regulatory changes or enforcement actions.